Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

VKVeronika KapustováLBLucie BroskevičováTPTereza Popková

Discussion

Loading...

Member takes

Overview

High levels of CD38+ NK cells correlate with worse progression-free survival in multiple myeloma, indicating treatment resistance.

Key Points

  • To identify immune cell subsets associated with treatment efficacy and resistance to anti-CD38 therapy in multiple myeloma.
  • Analyzed bone marrow samples from relapsed/refractory multiple myeloma patients receiving anti-CD38 therapy.
  • Used EuroFlow 8-color panel and high-dimensional spectral cytometry for immune profiling.
  • Assessed relationships between immune cell proportions and progression-free survival.
  • High baseline CD38+ NK cell levels significantly associated with poorer progression-free survival.
  • Mature B cells correlated with improved survival outcomes.
  • Post-treatment analysis showed decreased total NK and B cells, and increased T cells.

Cite This Study

Kapustová et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d5https://doi.org/10.1182/blood-2025-5720
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD8+CD38+ T cells Identify Functional High-Risk Multiple Myeloma After Autologous Transplant: BTM CTN 0702 Correlates2026
  2. 2NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma.2024 · 21 citations
  3. 3NK cell dysregulation in the multiple myeloma: insights from multi-modal profiling of the bone marrow microenvironment 28122025
  4. 4Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma2024
  5. 5Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective2026 · 4 citations